2021-09-19| Special

Day 2 ESMO 2021 Roundup: New Paradigms for Long-Term Cancer Care and Immunotherapies for High Risk Metastatic Cancers

by GeneOnline
Share To
The first keynote lecture of the 2021 ESMO annual meeting was given by Nobel laureate, Dr. William Kaelin of the Dana-Farber Cancer Institute in Boston. Dr. Kaelin on the reemerging principles of cancer therapy and how combination therapies are more effective in long-term cancer care.

To begin with, Dr. Kaelin explained how the most successful approaches in cancer treatment are when an initial, truncal genetic event is targeted instead of the branch mutations that occur later in a tumor’s evolution. Some of the successfully approved precision oncology drugs have been those that targeted proteins that have a good genetic validation as well as a fairly deep biological understanding.

However, there have been many that have remained undruggable despite extensive evaluation. For those, it would be better to exploit epistatic relationships by targeting druggable critical downstream effectors. There is also renewed interest in developing allosteric inhibitors that can indirectly inactive proteins through protein folding changes. Recently, various small molecule degraders have also entered the scene.

GO Prime with only $1.49 now

Biotech Showcase 2022: Healing the Psyche with Psychedelia
Sex Dimorphism in Obesity and the Impact of Estrogen Hormone Therapy on Cardiometabolic Health
ARM 2022: Industry Briefs on Cell and Gene Therapies
Study Reveals a Form of Four-Stranded DNA that Links Protein Deficiency and Premature Aging
Shanghai’s Everest Medicines Licenses Covid-19 Oral Antivirals from Singapore’s National Drug Discovery Platform
Digital Health Programme to Connect British and Taiwanese Leaders
Pfizer: Pneumonia Shot Can Be Given with COVID-19 Vaccine in Older Adults
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!